Search research articles
Contact Us
Filters
Showing results (281-290 of 346) with videos related to
Page
of 35
Sort By:
Blood Advances
|
April 22, 2021
Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax
Curtis A Lachowiez, Sanam Loghavi, Ken Furudate, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 16, 2023
Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies
Jayastu Senapati, Warren C Fiskus, Naval Daver, et al.
Blood Cancer Journal
|
June 29, 2023
A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis
Jayastu Senapati, Muharrem Muftuoglu, Jo Ishizawa, et al.
Blood Advances
|
May 27, 2026
Long-Term Outcomes of Azacitidine, Venetoclax and Gilteritinib in Newly Diagnosed FLT3-Mutated AML
Nicholas J Short, Hagop M Kantarjian, Naval G Daver, et al.
Leukemia
|
February 27, 2020
A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia
Prithviraj Bose, Srdan Verstovsek, Jorge E Cortes, et al.
Blood Advances
|
August 16, 2022
Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome
Courtney D DiNardo, Sangeetha Venugopal, Curtis Lachowiez, et al.
Bone Marrow Transplantation
|
April 11, 2025
Barriers to allogeneic stem cell transplantation in responding patients with TP53-mutated acute myeloid leukemia
Jayastu Senapati, Guillermo Garcia-Manero, Courtney D DiNardo, et al.
Cancer
|
August 9, 2025
Outcomes of patients with newly diagnosed acute myeloid leukemia with FLT3-tyrosine kinase domain mutations: Prognostic implications of NPM1 co-mutation
Sankalp Arora, Wei-Ying Jen, Musa Yilmaz, et al.
Blood Cancer Journal
|
September 22, 2023
Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents
Danielle Hammond, Sanam Loghavi, Sa A Wang, et al.
Blood
|
April 3, 2025
Blood-Based Proteomic Profiling Identifies OSMR as a Novel Biomarker of AML Outcomes
Patrick K Reville, Bofei Wang, Jennifer Marvin-Peek, et al.
Page
of 35
Search research articles
Search
Showing results (281-290 of 346) with videos related to
Sort By:
Page
of 35
Blood Advances
|
April 22, 2021
Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax
Curtis A Lachowiez, Sanam Loghavi, Ken Furudate, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 16, 2023
Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies
Jayastu Senapati, Warren C Fiskus, Naval Daver, et al.
Blood Cancer Journal
|
June 29, 2023
A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis
Jayastu Senapati, Muharrem Muftuoglu, Jo Ishizawa, et al.
Blood Advances
|
May 27, 2026
Long-Term Outcomes of Azacitidine, Venetoclax and Gilteritinib in Newly Diagnosed FLT3-Mutated AML
Nicholas J Short, Hagop M Kantarjian, Naval G Daver, et al.
Leukemia
|
February 27, 2020
A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia
Prithviraj Bose, Srdan Verstovsek, Jorge E Cortes, et al.
Blood Advances
|
August 16, 2022
Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome
Courtney D DiNardo, Sangeetha Venugopal, Curtis Lachowiez, et al.
Bone Marrow Transplantation
|
April 11, 2025
Barriers to allogeneic stem cell transplantation in responding patients with TP53-mutated acute myeloid leukemia
Jayastu Senapati, Guillermo Garcia-Manero, Courtney D DiNardo, et al.
Cancer
|
August 9, 2025
Outcomes of patients with newly diagnosed acute myeloid leukemia with FLT3-tyrosine kinase domain mutations: Prognostic implications of NPM1 co-mutation
Sankalp Arora, Wei-Ying Jen, Musa Yilmaz, et al.
Blood Cancer Journal
|
September 22, 2023
Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents
Danielle Hammond, Sanam Loghavi, Sa A Wang, et al.
Blood
|
April 3, 2025
Blood-Based Proteomic Profiling Identifies OSMR as a Novel Biomarker of AML Outcomes
Patrick K Reville, Bofei Wang, Jennifer Marvin-Peek, et al.
Page
of 35